IL-21-Reprogrammed Vδ1 T Cells Exert Killing against Solid Tumors Which Is Enhanced by CAR Arming for Off-the-Shelf Immunotherapy

When engineered with a CAR, Vδ1 T cells exhibited further enhanced anti-tumor efficacy in an immunodeficient NRG xenograft model of human ovarian cancer. These findings highlight K562-mb-IL-21 expanded peripheral blood Vδ1 T cells as a promising ‘off-the-shelf’ allogeneic therapy for solid tumors.